Elsevier

Neuroscience

Volume 63, Issue 4, December 1994, Pages 1003-1020
Neuroscience

Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain

https://doi.org/10.1016/0306-4522(94)90568-1Get rights and content

Abstract

The purpose of the following experiments was to describe some of the neurochemical changes that occur in the basal ganglia of rats exposed chronically to a classical neuroleptic, fluphenazine, and to relate these changes to extrapyramidal motor dysfunction. For these studies a combination of behavioural, receptor autoradiographic and in situ hybridization methods were employed. Preliminary pharmacological studies on GABA receptors showed that incubation in Tris-acetate rather than Tris-citrate buffer increased the number of binding sites labelled by [3H]muscimol by over 120% without affecting binding affinity or selectivity. The results of experiments with fluphenazine showed that treatment for six months increased the frequency of vacuous chewing movements compared to controls. In the striatum, changes in GABA transmission were observed in fluphenazine-treated rats with increases in glutamate decar☐ylase mRNA levels in the caudate nucleus, dorsal shell and core of the accumbens and decreases in [3H]muscimol binding in the caudate and dorsal shell regions. These data suggest that fluphenazine treatment increased GABA transmission in specific subregions of the candate and accumbens nuclei. In addition, glutamate decar☐ylase mRNA levels were elevated in the entopeduncular nucleus of fluphenazine-treated animals. Autoradiographic analysis of excitatory amino acid binding showed that fluphenazine exposure decreased [3H]α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding in entopeduncular nucleus and in the ventrolateral thalamic nucleus and decreased [3H]dizocilpine maleate binding in the medial geniculate nucleus.

These experiments show that in addition to altering GABA transmission, chronic neuroleptic exposure alters excitatory amino acid transmission in specific regions of the basal ganglia-thalamocortical motor system. The neuroleptic dependent increases in glutamate decar☐ylase mRNA levels in the entopeduncular nucleus may reflect changes in neurotransmission in the indirect pathway connecting the major input and output nuclei of the basal ganglia. Changes in some of these brain regions may be related to the occurrence of extrapyramidal motor disturbances.

Reference (83)

  • MercuglianoM. et al.

    Clozapine decreases enkephalin mRNA in rat striatum

    Neurosci. Lett.

    (1992)
  • MonaghanD.T. et al.

    Distribution of [3H]AMPA binding sites in rat brain as determined by quantitative autoradiography

    Brain Res.

    (1984)
  • MunsonP.J. et al.

    Ligand: a versatile computerized approach for characterization of ligand-binding systems

    Analyt. Biochem.

    (1980)
  • NakanishiH. et al.

    Intracellular study of rat entopeduncular nucleus neurons in an in vitro slice preparation: response to subthalamic stimulation

    Brain Res.

    (1991)
  • PapaS.M. et al.

    Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonist

    Eur. J. Pharmac.

    (1993)
  • PendeM. et al.

    Release of endogenous glutamic and aspartic acids from cerebrocortex synaptosomes and its modulation through the activation of γ-aminobutyric acidB (GABAB) receptor subtype

    Brain Res.

    (1993)
  • RobledoP. et al.

    Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data

    Brain Res.

    (1990)
  • SchumacherM. et al.

    Regulation of high-affinity GABAA receptors in the dorsal hippocampus by estradiol and progesterone

    Brain Res.

    (1989)
  • SoghomonianJ.J. et al.

    Messenger RNAs encoding glutamate-decar☐ylases are differentially affected by nigrostriatal lesions in subpopulations of striatal neurons

    Brain Res.

    (1992)
  • TanakaY. et al.

    Changes in γ-aminobutyrate, glutamate, aspartate, glycine and taurine contents in the striatum after unilateral nigrostriatal lesions in rats

    Expl Neurol.

    (1986)
  • VoloshinM.Y. et al.

    Participation of nucleus entopeduncularis in motor instrumental reflex and entopeduncular influences on motor thalamic nuclei in normal and MPTP-treated cats

    Neuroscience

    (1993)
  • BergmanH. et al.

    Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

    Science

    (1990)
  • BjörklundA. et al.

    Dopamine-containing systems in the CNS

  • BradfordM.M.

    A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye coupling

    Analyt. Biochem.

    (1976)
  • BrotchieJ.M. et al.

    Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate

    Mov. Disord.

    (1991)
  • BurnsR.S. et al.

    A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

  • CabocheJ. et al.

    Parallel decrease of glutamic acid decar☐ylase and proenkephalin mRNA in the rat striatum following chronic treatment with a dopaminergic D1 antagonist and D2 agonist

    J. Neurochem.

    (1991)
  • CabocheJ. et al.

    Role of dopaminergic D2 receptors in the regulation of glutamic acid decar☐ylase messenger RNA in the striatum of the rat

    Eur. J. Neurosci.

    (1992)
  • CalabresiP. et al.

    Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission

    Ann. Neurol.

    (1992)
  • CalabresiP. et al.

    Involvement of GABA systems in feedback regulation of glutamate- and GABA-mediated synaptic potentials in rat neostriatum

    J. Physiol.

    (1991)
  • CarlssonM. et al.

    The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

    J. neural. Transm.

    (1989)
  • CaseyD.E.

    Tardive dyskinesia

  • CohenB.M. et al.

    Plasma levels of neuroleptic in patients receiving depot fluphenazine

    J. Clin. Psychopharmac.

    (1985)
  • CreeseI.

    Biochemical properties of CNS dopamine receptors

  • Dahl-PuustinenM.-L. et al.

    Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

    Clin. Pharmac. Ther.

    (1989)
  • De KeyserJ.

    Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia

    Clin. Neuropharmac.

    (1991)
  • De PlazasS.F. et al.

    Methods for removing endogenous factors from CNS membrane preparations: Differences in [3H] GABA binding parameters and developmental-related effects

    Neurochem. Res.

    (1993)
  • EsclapezM. et al.

    Comparative localization of mRNAs encoding two forms of glutamic acid decar☐ylase with nonradioactive in situ hybridization methods

    J. comp. Neurol.

    (1993)
  • FardeL. et al.

    Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects

    Arch. gen. Psych.

    (1992)
  • FeldblumS. et al.

    Different distributions of GAD65 and GAD67 mRNAS suggest that the two glutamate decar☐ylases play distinctive functional roles

    J. Neurosci. Res.

    (1993)
  • FibigerH.C. et al.

    Neurobiological substrates of tardive dyskinesia: The GABA hypothesis

    Trends Neurosci.

    (1984)
  • Cited by (27)

    • Antipsychotic-evoked dopamine supersensitivity

      2020, Neuropharmacology
      Citation Excerpt :

      Chronic antipsychotic treatment produces subtle changes in AMPA and NMDA levels in the striatum. There are no significant changes in the overall density of striatal NMDA or AMPA receptors, or NMDA receptor 1 or 2 subunits (Johnson et al., 1994; Meshul et al., 1996; Scarr et al., 2002; Hanaoka et al., 2003; Oda et al., 2017). However, there can be cell type-specific effects.

    • Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: A follow-up study in antipsychotic-naïve patients with first-episode psychosis

      2014, Journal of Psychiatric Research
      Citation Excerpt :

      Two other animal studies have demonstrated that risperidone reduces GABA levels in certain brain areas in rats (Grimm and See, 1998; Kikumoto et al., 1993). Moreover, changes in GAD67 expression are different among typical and atypical antipsychotics (Chen and Weiss, 1993; Delfs et al., 1995; Johnson et al., 1994; Laprade and Soghomonian, 1995; Sakai et al., 2001) and GABA concentrations (Tayoshi et al., 2010). In addition, Tayoshi et al. (2010) suggested that all antipsychotic medications might decrease GABA concentrations in the anterior cingulate cortex, as these authors observed a significantly negative correlation between GABA concentrations and antipsychotic doses.

    • GABA concentration in schizophrenia patients and the effects of antipsychotic medication: A proton magnetic resonance spectroscopy study

      2010, Schizophrenia Research
      Citation Excerpt :

      Our study has demonstrated that the in vivo GABA concentrations of the ACC and the ltBG did not differ significantly between medicated chronic schizophrenia patients and healthy control subjects. Animal studies have reported that typical antipsychotics increased the expression of GAD67 and GAD67 mRNA in the basal ganglia (Chen and Weiss, 1993; Johnson et al., 1994; Jolkkonen et al., 1994; Delfs et al., 1995a,b; Laprade and Soghomonian, 1995; Sakai et al., 2001), but that administration of atypical antipsychotic drugs did not (Delfs et al., 1995a; Sakai et al., 2001). Our observation of significantly higher GABA concentrations in the TYP group compared to the ATY group is therefore compatible with the findings of these animal studies.

    View all citing articles on Scopus
    View full text